Welcome to LookChem.com Sign In|Join Free
  • or
Hederagonic acid, also known as 3,4-dihydroxyolean-12-enoic acid, is a triterpenoid compound derived from various plant sources, such as Hedera helix (common ivy) and Pulsatilla chinensis. It exhibits anti-inflammatory, anti-cancer, and anti-fibrotic properties, positioning it as a potential therapeutic agent for a range of medical conditions. Its ability to inhibit cancer cell growth, reduce inflammation, and prevent excessive scar tissue formation has garnered significant interest in the pharmaceutical field. Hederagonic acid is also recognized for its safety and non-toxicity, making it a promising candidate for further development and clinical applications.

466-01-3

Post Buying Request

466-01-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

466-01-3 Usage

Uses

Used in Pharmaceutical Industry:
Hederagonic acid is used as an anti-inflammatory agent for its capacity to reduce inflammation, which can be beneficial in treating various inflammatory conditions.
Hederagonic acid is used as an anti-cancer agent for its ability to inhibit the growth of cancer cells, making it a potential therapeutic option for cancer treatment.
Hederagonic acid is used as an anti-fibrotic agent for its potential to prevent excessive scar tissue formation, which can be applied in the treatment of liver fibrosis, pulmonary fibrosis, and other fibrotic disorders.
While the provided materials do not specify different applications in various industries, the uses listed are based on the compound's properties and potential therapeutic effects in the medical and pharmaceutical fields. Further research and development could reveal additional applications in other industries.

Check Digit Verification of cas no

The CAS Registry Mumber 466-01-3 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 4,6 and 6 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 466-01:
(5*4)+(4*6)+(3*6)+(2*0)+(1*1)=63
63 % 10 = 3
So 466-01-3 is a valid CAS Registry Number.

466-01-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name Hederagonic acid

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:466-01-3 SDS

466-01-3Downstream Products

466-01-3Relevant academic research and scientific papers

Design, synthesis, and biological evaluation of hederagenin derivatives with improved aqueous solubility and tumor resistance reversal activity

Wang, Binghua,Liu, Shuqi,Huang, Wentao,Ma, Mengxin,Chen, Xiaoqian,Zeng, Wenxuan,Liang, Kaicheng,Wang, Hongbo,Bi, Yi,Li, Xiaopeng

, (2020/12/29)

Multidrug resistance (MDR) has become a major obstacle to malignancies treatment by chemotherapeutic drugs, therefore, it is important to develop MDR reversal agents with high activity. We have previously found that the hederagenin (HD) derivative HBQ showed good tumor MDR reversal activity in vitro and in vivo but had poor solubility. In this study, to enhance the aqueous solubility and tumor MDR reversal activity of HBQ, three series of HD derivatives were designed and synthesized. Nitrogen-containing heterocyclic-substituted, PEGylated, and ring-A substituted derivatives significantly reversed the MDR phenotype of KBV (multidrug-resistant oral epidermoid carcinoma) cells toward paclitaxel at a concentration of 10 μM in MTT assays. The PEGylated derivatives 10c–10e had increased aqueous solubility compared with HBQ by 18–657 fold, while maintaining tumor MDR reversal activity. The most in vitro active compound 10c possessed good chemical stability to an esterase over 24 h and enhanced the sensitivity of KBV cells to paclitaxel and vincristine with IC50 values of 4.58 and 0.79 nM, respectively. Mechanism studies indicated that compound 10c increased the accumulation of P-glycoprotein (P-gp) substrates rhodamine 123 and Flutax1 in KBV cells and MCF-7T (paclitaxel-resistant breast carcinoma) cells, that is to say, compound 10c exerted the reversal effect of tumor MDR by inhibiting the efflux function of P-gp. Finally, the structure–activity relationships were further investigated by analyzing the relationship between structure and tumor MDR reversal activity of HD derivatives. This study highlights the potential of PEGylated HD derivatives such as compound 10c for the development of tumor MDR reversal agents and provides information for the further improvement of the aqueous solubility and tumor MDR reversal activity of HD derivatives in the future.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 466-01-3